Nov. 14, 2019: Psychiatric disorders, adherence, and viral suppression; depression and adherence among women with HIV; using hair to link food insecurity and HIV viremia; a point-of-care test for tenofovir adherence.
Nov. 7, 2019: Zoledronic acid to prevent bone loss; bone benefits for older patients switching from TDF to TAF; periperhal artery disease among women; motor dysfunction and cognitive impairment.
Oct. 31, 2019: HCV treatment efficacy regardless of injection drug use; chronic pain, marijuana, and prescription opoids; the most urgent HIV training priorities; neuro effects of switching from Atripla to Complera.
Oct. 3, 2019: The sexual divide in HIV-related heart disease; weight gain among women on integrase inhibitors; HIV's association with non-specific health conditions; hopeful trends in self-reported neurocognitive impairment.
Aug. 22, 2019: Links between thiamine deficiency and cognitive issues; HIV in cerebrospinal fluid and neurocognitive impairment; frailty, depression, and symptomatic cognitive issues; alcohol consumption and HIV disease progression.
This will likely become the landmark study about the overall rate of neuropsychiatric side effects with this class of medicines over the next several years.
April 11, 2019: acute syphilis and virologic control; neuropsychological performance after switching off efavirenz; structural LGBTQ stigma and HIV criminalization in U.S. states; lung cancer resection surgery in people with HIV.
More research is needed to understand the connections between HIV, mental health, and the neurocircuitry that controls executive function.
Internalized HIV stigma, depression, and adherence in women; what “internalized HIV stigma” actually means; tenofovir-containing gel and genital herpes prevention; the neurocognitive effects of cerebrospinal HIV escape.
HIV-associated neurocognitive disorders, including dementia, may be well-documented issues, but they're still being understood. New research answers some questions providers may have about HIV's impact on the brain.